Ethical Dilemma with Stakeholders
You're the CEO of a pharmaceutical company. Your best-selling drug ($2B annual revenue, used by 4 million patients for chronic pain) has…
Assuming this is a U.S.-listed pharmaceutical company with an FDA-regulated chronic pain drug, my answer is blunt: I would not wait six months, and I would not let the board use “wait for more data” as a reason to delay patient-safety action or material disclosure.Read the full answer



